Sitagliptin/Metformin AL, manufactured by Aliud Pharma GmbH (Germany), is a film-coated tablet combining sitagliptin (50 mg), a DPP-4 inhibitor, and metformin hydrochloride (1000 mg), a biguanide. This dual-action therapy improves glycemic control in adults with type 2 diabetes mellitus, particularly when diet and exercise alone are insufficient.
Mechanism of action:
-
Sitagliptin: Enhances the body’s own incretin hormones, increasing insulin secretion and decreasing glucagon levels after meals.
-
Metformin: Reduces glucose production in the liver, improves insulin sensitivity, and decreases intestinal glucose absorption.
Indications:
-
Adults with type 2 diabetes mellitus requiring dual therapy
-
As an alternative to separate administration of sitagliptin and metformin
-
Often used when monotherapy does not provide adequate glycemic control
Key benefits:
-
Convenient single tablet with dual glucose-lowering effect
-
Clinically proven to improve HbA1c levels
-
Well tolerated when used under medical supervision
-
Supports lifestyle interventions (diet and exercise)
⚠️ Important safety information:
-
Prescription-only medicine
-
Not for use in type 1 diabetes, diabetic ketoacidosis, or severe kidney/liver impairment
-
May cause gastrointestinal side effects (nausea, diarrhea) or rare lactic acidosis
-
Regular monitoring of kidney function and blood glucose recommended
Form: Film-coated tablets
Pack size: 56 tablets
Manufacturer: Aliud Pharma GmbH, Germany
